Efficacy and Safety of Generic Amphotericin B in Experimental Pulmonary Aspergillosis-Reference-Cited by-同舟云学术

Efficacy and Safety of Generic Amphotericin B in Experimental Pulmonary Aspergillosis

Published:2005-04 Issue:4 Volume:49 Page:1642-1645
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Petraitis Vidmantas¹²,Petraitiene Ruta¹²,Lin Pengxin¹,Calis Karim³,Kelaher Amy M.¹,Muray Heidi A.¹,Mya-San Christine¹,Mickiene Diana¹,Bacher John⁴,Walsh Thomas J.¹

Affiliation:

1. Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute

2. SAIC-Frederick, Inc., Frederick, Maryland

3. Pharmacy Department, Warren-Grant Magnuson Clinical Center, Bethesda

4. Surgery Service, Veterinary Resources Program, Office of Research Services, National Institutes of Health

Abstract

ABSTRACT The recent shortage of the brand name drug Fungizone has necessitated a change to generic formulations of amphotericin B deoxycholate. Clinical trials cannot be conducted in a timely manner to provide data on the safety and efficacy of these formulations. We therefore compared generic amphotericin B and Fungizone for activity and safety in the treatment of experimental invasive pulmonary aspergillosis (IPA) in persistently neutropenic rabbits. Fungizone and generic amphotericin B are similar in efficacy, pharmacokinetics, and safety in the treatment of experimental IPA.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.49.4.1642-1645.2005

Reference17 articles.

1. Alexander, M. R. 1974. Review of vancomycin after 15 years of use. Drug Intell. Clin. Pharm.8:520.

2. Anaissie, E. 1992. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin. Infect. Dis.14(Suppl. 1):S43-S53.

3. Cleary, J. D., P. D. Rogers, and S. W. Chapman. 2003. Variability in polyene content and cellular toxicity among deoxycholate amphotericin B formulations. Pharmacotherapy23:572-578.

4. Denning, D. W. 2001. Chronic forms of pulmonary aspergillosis. Clin. Microbiol. Infect.7(Suppl. 2):25-31.

5. Eng, R. H., L. Wynn, S. M. Smith, and F. Tecson-Tumang. 1989. Effect of intravenous vancomycin on renal function. Chemotherapy35:320-325.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modeling Invasive Aspergillosis: How Close Are Predicted Antifungal Targets?;Journal of Fungi;2020-09-30

2. Animal Models for Studying Triazole Resistance in Aspergillus fumigatus;The Journal of Infectious Diseases;2017-08-15

3. Antifungal Pharmacokinetics and Pharmacodynamics;Methods in Pharmacology and Toxicology;2016

4. Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis;PLOS ONE;2015-11-04

5. Efficacy of an Abbreviated Induction Regimen of Amphotericin B Deoxycholate for Cryptococcal Meningoencephalitis: 3 Days of Therapy Is Equivalent to 14 Days;mBio;2014-02-28